![Rasmus Holm-Jorgensen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rasmus Holm-Jorgensen
Directeur Financier/CFO chez ACRIVON THERAPEUTICS, INC.
Fortune : 158 096 $ au 30/06/2024
Postes actifs de Rasmus Holm-Jorgensen
Sociétés | Poste | Début | Fin |
---|---|---|---|
ACRIVON THERAPEUTICS, INC. | Directeur Financier/CFO | 01/04/2022 | - |
Historique de carrière de Rasmus Holm-Jorgensen
Anciens postes connus de Rasmus Holm-Jorgensen
Sociétés | Poste | Début | Fin |
---|---|---|---|
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC | Fondateur | 01/07/2015 | 01/04/2022 |
Corporate Officer/Principal | 01/07/2015 | 01/04/2022 | |
SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01/01/2011 | 01/01/2015 |
Formation de Rasmus Holm-Jorgensen
University of Copenhagen | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Danemark | 2 |
Opérationnelle
Corporate Officer/Principal | 2 |
Founder | 1 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ACRIVON THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Kiniksa Pharmaceuticals Ltd.
![]() Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA. | Health Technology |
Synageva BioPharma Corp.
![]() Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Bourse
- Insiders
- Rasmus Holm-Jorgensen
- Expérience